Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Biogen Idec to acquire Fumapharm AG; Consolidates ownership of oral compound BG-12 being studied for multiple sclerosis
Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study.
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex (SYNERGY)
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study.
Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?
MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study.
Pregnancy and multiple sclerosis.
Extracellular Cues Influencing Oligodendrocyte Differentiation and (Re)myelination.
Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis.
A New Colour Reaction on Copper and Certain Carbonyl Compounds
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
De- and remyelination in the CNS white and grey matter induced by cuprizone: the old, the new, and the unexpected.
Inhibition of LINGO-1 promotes functional recovery after experimental spinal cord demyelination.
Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-β1a in Relapsing-Remitting Multiple Sclerosis.
Meta-analysis of adverse events in recent randomized clinical trials for dimethil fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis.
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Neuroprotective dimethyl fumarate synergizes with immunomodulatory interferon beta to provide enhanced axon protection in autoimmune neuroinflammation.
Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis.
Birth Outcomes in Newborns Fathered by Men with Multiple Sclerosis Exposed to Disease-Modifying Drugs.
Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis.
Status spongiosus of CNS and hepatic changes induced by cuprizone (biscyclohexanone oxalyldihydrazone).
Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.
MS clinical trials: what can subgroup analyses teach us?
Delayed visual evoked response in optic neuritis.

Pages